The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Vaccination strategies based on the in vivo targeting of Ags to dendritic cells (DCs) are needed to improve the induction of specific T cell immunity against tumors and infectious agents. In this study, we have used a recombinant protein encompassing the extra domain A from fibronectin (EDA), an endogenous ligand for TLR4, to deliver Ags to TLR4-expressing DC. The purified EDA protein was shown to bind to TLR4-expressing HEK293 cells and to activate the TLR4 signaling pathway. EDA also stimulated the production by DC of proinflammatory cytokines such as IL-12 or TNF-α and induced their maturation in vitro and in vivo. A fusion protein between EDA and a cytotoxic T cell epitope from OVA efficiently presented this epitope to specific T cells and induced the in vivo activation of a strong and specific CTL response. Moreover, a fusion protein containing EDA and the full OVA also improved OVA presentation by DC and induced CTL responses in vivo. These EDA recombinant proteins protected mice from a challenge with tumor cells expressing OVA. These results strongly suggest that the fibronectin extra domain A may serve as a suitable Ag carrier for the development of antiviral or antitumoral vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vabulas, R. M., Ahmad-Nejad, P., da Costa, C., Miethke, T., Kirschning, C. J., Häcker, H., & Wagner, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103217200 · Cited by 805 · cited 1×
“Indeed, TLR4, which is able to recognize LPS, can also be activated by Hsp60 (18, 19) and by the spliced exon encoding the type III repeat extra domain A (EDA) from fibronectin (20).”
Background
Cited by
The role of synovitis in osteoarthritis pathogenesis
Scanzello, C. R., & Goldring, S. R. (2012) · Bone · doi:10.1016/j.bone.2012.02.012 · Cited by 1,302
Macrophage activation by endogenous danger signals
Zhang, X., & Mosser, D. (2008) · The Journal of Pathology · doi:10.1002/path.2284 · Cited by 611
Leaphart, C. L., Cavallo, J., Gribar, S. C., Cetin, S., Li, J., Branca, M. F., Dubowski, T. D., Sodhi, C. P., & Hackam, D. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4808 · Cited by 480
Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?
Scanzello, C. R., Plaas, A., & Crow, M. K. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32830aba34 · Cited by 268
White, E. S., & Muro, A. F. (2011) · IUBMB Life · doi:10.1002/iub.493 · Cited by 174
“As the first description of the EDA domain activates TLR4, numerous functions have been ascribed to this interaction such as arterial remodeling in atherosclerosis (65), induction of cytotoxic T cell responses following antigen stimulation (66), stimulation of mast cells (67), and priming of leukotriene synthesis in n…”
BackgroundTLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings
Shetab Boushehri, M. A., & Lamprecht, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00691 · Cited by 161
Jin, J.-O., Zhang, W., Du, J.-Y., Wong, K.-W., Oda, T., & Yu, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099396 · Cited by 160
“DCs are known to prime CTL responses upon activation by ligands targeting several PRRs, including toll-like receptors and Dectin-1 [33,34].”
Background
Metadata
- Authors
- Lasarte, J. J., Casares, N., Gorraiz, M., Hervás-Stubbs, S., Arribillaga, L., Mansilla, C., Durantez, M., Llopiz, D., Sarobe, P., Borrás-Cuesta, F., Prieto, J., & Leclerc, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01
- Volume
- 178
- Issue
- 2
- Pages
- 748-756
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1760966156
- Cited by
- 103
- References
- 1
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.